Modification of plasma insulin-like growth factors and binding proteins during oral contraceptive use and the normal menstrual cycle, ,

Objective: Sex steroid regulation of the insulin-like growth factor axis is a subject of contention. We examined the effect of combined oral contraceptives and investigated the cyclic variations in the insulin-like growth factor axis. Study Design: Fasting blood samples were taken from 9 women receiving oral contraceptives, 10 women receiving no medication, and 10 male subjects. Results: In women receiving oral contraceptives, insulin-like growth factor binding protein 1 remained highly phosphorylated and levels were acutely increased by sex steroid treatment (305 ± 110 μg/L on day 14 of the cycle [medication phase] vs 118 ± 70 μg/L during the medication-free period, P< .03). In women receiving no medication, insulin-like growth factor binding protein 1 levels were significantly lower (69 ± 50 μg/L on day 14 of the menstrual cycle, P< .001) and varied cyclically, with a rise in the late-secretory phase that coincided with the appearance of nonphosphorylated and less phosphorylated insulin-like growth factor binding protein 1 isoforms. Compared with those in untreated women and in men, insulin-like growth factor I levels were decreased in women receiving oral contraceptives (405 ± 104 ng/mL in untreated women and 330 ± 28 ng/mL in men vs 287 ± 73 ng/mL in women receiving oral contraceptives, P< .004). Oral contraceptive use had no effect on insulin-like growth factor II levels, and neither insulin-like growth factor I nor insulin-like growth factor II showed cyclic variation. Conclusion: The bioavailability of insulin-like growth factor I is reduced in users of oral contraceptives. This may contribute to the metabolic changes observed in such subjects. (Am J Obstet Gynecol 1999;180:530-6.)